ArticleOncogene2005
Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling.
Article in Oncogene, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Mechanisms of non-metastatic 2 (NME2)-mediated control of metastasis across tumor types.Naunyn-Schmiedeberg's archives of pharmacology · 2011Pooled it
- Non-apoptotic caspase events and Atf3 expression underlie direct neuronal differentiation of adult neural stem cells.Development (Cambridge, England) · 2024Article
- ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC.Cell death & disease · 2024Article
- Integrated Stress Response (ISR) Pathway: Unraveling Its Role in Cellular Senescence.International journal of molecular sciences · 2023Review
- Targeting purine metabolism in ovarian cancer.Journal of ovarian research · 2022Review
- Lysophosphatidic Acid Signaling and microRNAs: New Roles in Various Cancers.Frontiers in oncology · 2022Review
- STARD3: A Prospective Target for Cancer Therapy.Cancers · 2021Review
- Progesterone suppresses the progression of colonic carcinoma by increasing the activity of the GADD45α/JNK/c‑Jun signalling pathway.Oncology reports · 2021Observational
- ATF3 deficiency impairs the proliferative-secretory phase transition and decidualization in RIF patients.Cell death & disease · 2021Article
- Article
- Time-Resolved Profiling Reveals ATF3 as a Novel Mediator of Endocrine Resistance in Breast Cancer.Cancers · 2020Article
- Different Role of Caveolin-1 Gene in the Progression of Gynecological Tumors.Asian Pacific journal of cancer prevention : APJCP · 2019Review
- Progesterone reduces cell survival in primary cultures of endometrioid ovarian cancer.Journal of ovarian research · 2019Article
- ATF3 Repression of BCL-XClinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.Oncotarget · 2017Article
- Activating transcription factor 3 promotes embryo attachment via up-regulation of leukemia inhibitory factor in vitro.Reproductive biology and endocrinology : RB&E · 2017Article
- Activating transcription factor 3 promotes malignance of lung cancer cells in vitro.Thoracic cancer · 2017Article
- Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.Oncotarget · 2017Article
- Nestin suppression attenuates invasive potential of endometrial cancer cells by downregulating TGF-β signaling pathway.Oncotarget · 2016Article
- ARHGAP10, downregulated in ovarian cancer, suppresses tumorigenicity of ovarian cancer cells.Cell death & disease · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Although progesterone (P4) has been implicated to offer protection against ovarian cancer (OCa), little is known of its mechanism of action. The goal of this study was to identify P4-regulated genes that have anti-OCa action. Three immortalized nontumorigenic human ovarian surface epithelial (HOSE) cell lines and three OCa (OVCA) cell lines were subjected to 5 days of P4 treatment. Transcriptional profiling with a cDNA microarray containing approximately 2400 known genes was used to identify genes (1) whose expression was consistently downregulated in OVCA cell lines compared to HOSE cell lines, and (2) whose expression was restored in OCa cell lines by P4 treatment. From the candidates selected, activating transcription factor-3 (ATF-3), caveolin-1, deleted in liver cancer-1 (DLC-1), and nonmetastatic clone 23 (NM23-H2) were chosen for post hoc functional studies based on their previously reported action as tumor suppressors or apoptosis inducers. Semiquantitative RT-PCR analyses confirmed loss of or reduced transcription of these genes in OVCA cells when compared to HOSE cells and their upregulation following P4 treatment. Hormonal specificity was demonstrated by blockade experiments with a progestin antagonist RU 38486. Ectopic expression of caveolin-1, DLC-1, and NM23-H2 caused growth inhibition in OVCA cell cultures, but not in HOSE cell cultures, while forced expression of ATF-3 suppressed growth in both. Overexpression of AFT-3 also enhanced caspase-3 activity in both HOSE and OVCA cells, whereas ectopic expression of caveolin-1 and DLC-1 only activated this enzyme in OCa cells. In contrast, NM23-H2 overexpression was ineffective in activating caspase-3. Overexpression of any of the four genes in OCa cells reduced soft-agar colony formation and cell invasiveness. Taken together, we have identified four new P4-regulated, antitumor genes for OCa. However, their modes of action differ significantly; ATF-3 primarily functions as an apoptosis inducer, NM23-H2 as a suppressor of cell motility, and caveolin-1 and DLC-1 exhibiting features of classical tumor suppressors. To the best of our knowledge, except for NM23-H2, this is the first report linking P4 to the regulation of these tumor suppressor/proapoptotic genes, which could serve as future therapeutic targets.
Indexed as
Identifiers
15674352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.